Neurogene (NASDAQ:NGNE) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Neurogene (NASDAQ:NGNE) in a research note issued to investors on Friday, Benzinga reports. HC Wainwright currently has a $55.00 price target on the stock.

NGNE has been the topic of a number of other research reports. SVB Leerink began coverage on shares of Neurogene in a report on Monday, April 29th. They issued an outperform rating and a $46.00 price target on the stock. Stifel Nicolaus began coverage on shares of Neurogene in a report on Friday, January 5th. They issued a buy rating and a $31.00 price target on the stock. Leerink Partnrs reissued an outperform rating on shares of Neurogene in a report on Monday, April 29th. William Blair assumed coverage on shares of Neurogene in a research note on Thursday, March 21st. They set an outperform rating and a $61.00 target price on the stock. Finally, TD Cowen assumed coverage on shares of Neurogene in a research note on Thursday, January 4th. They set an outperform rating on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $48.25.

Neurogene Stock Performance

Shares of Neurogene stock opened at $32.81 on Friday. The company has a market cap of $422.13 million, a price-to-earnings ratio of -2.64 and a beta of 1.36. Neurogene has a 12-month low of $12.20 and a 12-month high of $53.00. The stock has a fifty day moving average price of $38.36.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Neurogene during the 1st quarter valued at about $120,000. Privium Fund Management UK Ltd purchased a new position in Neurogene in the first quarter worth about $274,000. BML Capital Management LLC purchased a new position in Neurogene in the fourth quarter worth about $478,000. Avidity Partners Management LP purchased a new position in Neurogene in the fourth quarter worth about $9,036,000. Finally, Great Point Partners LLC purchased a new position in Neurogene in the fourth quarter worth about $19,268,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.